• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

根治性切除术治疗胆管癌患者围手术期化疗对生存的影响。

Impact of perioperative chemotherapy on survival in patients with cholangiocarcinoma undergoing curative resection.

机构信息

Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

Department of Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, USA.

出版信息

Eur J Surg Oncol. 2023 Nov;49(11):106994. doi: 10.1016/j.ejso.2023.106994. Epub 2023 Jul 27.

DOI:10.1016/j.ejso.2023.106994
PMID:37524649
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11552685/
Abstract

BACKGROUND

Most patients with localized cholangiocarcinoma (CCA) endure cancer relapse after curative resection underscoring the importance of systemic therapy. The current study attempts to determine the impact of perioperative chemotherapy (PC) on survival in patients with CCA undergoing resection.

METHODS

Patients diagnosed with CCA undergoing curative-intent resection between January 1, 2000, and December 31, 2019, in a tertiary care center were included. Cox proportional hazard modeling was used to determine the impact of PC on disease-free survival (DFS) and overall survival (OS). In addition, a nomogram was constructed to estimate 3-year DFS.

RESULTS

Among the 182 patients included in the analysis, 102 underwent surgery alone, and 80 received surgery plus PC. Forty-two patients received neoadjuvant therapy, and 38 patients received adjuvant therapy. On multivariate analysis, PC was significantly associated with an improved DFS (HR, 95% CI: 0.63, 0.41-0.98; p = 0.04) and OS (HR, 95% CI: 0.46, 0.27-0.78; p < 0.01). In the interaction analysis, the survival benefit was especially seen in patients with positive resection margins and tumor size > 5 cm.

CONCLUSION

In patients with CCA undergoing curative resection, receipt of PC was associated with improved DFS and OS. The nomogram constructed from this database provides an estimate of 3-year DFS after surgical resection. Randomized trials are needed to define the optimal regimen and sequence.

摘要

背景

大多数局限性胆管癌(CCA)患者在根治性切除术后会经历癌症复发,这突显了全身治疗的重要性。本研究试图确定围手术期化疗(PC)对接受切除术的 CCA 患者生存的影响。

方法

纳入 2000 年 1 月 1 日至 2019 年 12 月 31 日在一家三级护理中心接受根治性切除术的 CCA 患者。使用 Cox 比例风险模型确定 PC 对无病生存率(DFS)和总生存率(OS)的影响。此外,构建了一个列线图来估计 3 年 DFS。

结果

在纳入分析的 182 名患者中,102 名仅接受手术,80 名接受手术加 PC。42 名患者接受新辅助治疗,38 名患者接受辅助治疗。多变量分析显示,PC 与改善的 DFS(HR,95%CI:0.63,0.41-0.98;p=0.04)和 OS(HR,95%CI:0.46,0.27-0.78;p<0.01)显著相关。在交互分析中,在切缘阳性和肿瘤大小>5cm 的患者中,生存获益尤其明显。

结论

在接受根治性切除术的 CCA 患者中,接受 PC 与改善的 DFS 和 OS 相关。从这个数据库构建的列线图提供了手术后 3 年 DFS 的估计。需要进行随机试验来确定最佳方案和顺序。

相似文献

1
Impact of perioperative chemotherapy on survival in patients with cholangiocarcinoma undergoing curative resection.根治性切除术治疗胆管癌患者围手术期化疗对生存的影响。
Eur J Surg Oncol. 2023 Nov;49(11):106994. doi: 10.1016/j.ejso.2023.106994. Epub 2023 Jul 27.
2
Efficacy and safety of adjuvant chemotherapy in T1N0M0 intrahepatic cholangiocarcinoma after radical resection.辅助化疗在根治性切除术后 T1N0M0 型肝内胆管细胞癌中的疗效和安全性。
BMC Cancer. 2022 Nov 10;22(1):1159. doi: 10.1186/s12885-022-10269-0.
3
Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma.可切除胆管癌的术后辅助化疗。
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD012814. doi: 10.1002/14651858.CD012814.pub2.
4
Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis.新辅助化疗与辅助化疗治疗胆管癌的比较:倾向评分匹配分析。
Eur J Surg Oncol. 2019 Aug;45(8):1432-1438. doi: 10.1016/j.ejso.2019.03.023. Epub 2019 Mar 21.
5
Should lymphadenectomy performed routinely in patients with primary intrahepatic cholangiocarcinoma undergoing curative hepatectomy? A retrospective cohort study with propensity-score matching analysis.在接受根治性肝切除的原发性肝内胆管细胞癌患者中,是否应常规进行淋巴结清扫术?一项采用倾向评分匹配分析的回顾性队列研究。
BMC Surg. 2023 Nov 30;23(1):364. doi: 10.1186/s12893-023-02255-5.
6
Neoadjuvant Chemotherapy for Intrahepatic, Perihilar, and Distal Cholangiocarcinoma: a National Population-Based Comparative Cohort Study.新辅助化疗治疗肝内、肝门周围和远端胆管癌:一项全国人群基于队列的比较研究。
J Gastrointest Surg. 2023 Apr;27(4):741-749. doi: 10.1007/s11605-023-05606-y. Epub 2023 Feb 7.
7
Locoregional recurrence after curative intent resection for intrahepatic cholangiocarcinoma: implications for adjuvant radiotherapy.肝内胆管癌根治性切除术后的局部区域复发:辅助放疗的意义
Clin Transl Oncol. 2015 Oct;17(10):825-9. doi: 10.1007/s12094-015-1312-0. Epub 2015 Jun 4.
8
The prognostic role of lymphovascular invasion and lymph node metastasis in perihilar and intrahepatic cholangiocarcinoma.肝门部和肝内胆管细胞癌中淋巴管侵犯和淋巴结转移的预后作用。
Eur J Surg Oncol. 2019 Aug;45(8):1468-1478. doi: 10.1016/j.ejso.2019.04.019. Epub 2019 Apr 25.
9
Impact of preoperative endoscopic ultrasound-guided fine needle aspiration on postoperative recurrence and survival in cholangiocarcinoma patients.术前内镜超声引导下细针抽吸对胆管癌患者术后复发和生存的影响。
Endoscopy. 2013 Nov;45(11):883-9. doi: 10.1055/s-0033-1344760. Epub 2013 Oct 28.
10
Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis.辅助经动脉化疗栓塞治疗对根治性切除术后合并肝细胞癌和胆管细胞癌患者的无复发生存和总体生存无影响:倾向评分匹配分析。
BMC Cancer. 2020 Jul 10;20(1):642. doi: 10.1186/s12885-020-07138-z.

引用本文的文献

1
Perihilar and Intrahepatic Cholangiocarcinoma after Resection: Clinicopathological Characteristics, Outcomes, and Implications for Addition of Chemoradiotherapy.肝门部及肝内胆管癌切除术后:临床病理特征、预后及放化疗加用的意义
Euroasian J Hepatogastroenterol. 2024 Jul-Dec;14(2):134-144. doi: 10.5005/jp-journals-10018-1440. Epub 2024 Dec 27.
2
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study.一项 II/III 期随机临床试验,比较顺铂联合吉西他滨和 Nab-紫杉醇(GAP)作为术前化疗与即刻切除术治疗高复发风险可切除胆道癌(BTC)患者的疗效:PURITY 研究。
BMC Cancer. 2024 Apr 8;24(1):436. doi: 10.1186/s12885-024-12225-6.
3
liver resection and auto-transplantation and special systemic therapy in perihilar cholangiocarcinoma treatment.肝门部胆管癌治疗中的肝切除与自体移植及特殊全身治疗
World J Gastrointest Surg. 2024 Mar 27;16(3):635-640. doi: 10.4240/wjgs.v16.i3.635.

本文引用的文献

1
Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017.美国 2001 至 2017 年胆管癌发病率和死亡率的时间变化。
Oncologist. 2022 Oct 1;27(10):874-883. doi: 10.1093/oncolo/oyac150.
2
Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)-Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC).寻找“沃尔多”:循环肿瘤DNA(ctDNA)指导的结直肠癌(CRC)微小残留病(MRD)评估的不断演变的范式
Cancers (Basel). 2022 Jun 23;14(13):3078. doi: 10.3390/cancers14133078.
3
Clinicopathological characteristics and prognostic factors for intrahepatic cholangiocarcinoma: a population-based study.肝内胆管细胞癌的临床病理特征和预后因素:一项基于人群的研究。
Sci Rep. 2021 Feb 17;11(1):3990. doi: 10.1038/s41598-021-83149-5.
4
Biliary tract cancer.胆道癌。
Lancet. 2021 Jan 30;397(10272):428-444. doi: 10.1016/S0140-6736(21)00153-7.
5
Minimal Residual Disease, Metastasis and Immunity.微小残留病灶、转移和免疫。
Biomolecules. 2021 Jan 20;11(2):130. doi: 10.3390/biom11020130.
6
Adjuvant chemotherapy for intrahepatic cholangiocarcinoma: approaching clinical practice consensus?肝内胆管癌的辅助化疗:达成临床实践共识?
Hepatobiliary Surg Nutr. 2020 Oct;9(5):577-586. doi: 10.21037/hbsn.2019.06.12.
7
Cholangiocarcinoma 2020: the next horizon in mechanisms and management.胆管癌 2020:机制和管理的新前沿。
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588. doi: 10.1038/s41575-020-0310-z. Epub 2020 Jun 30.
8
The role of down staging treatment in the management of locally advanced intrahepatic cholangiocarcinoma: Review of literature and pooled analysis.降期治疗在局部晚期肝内胆管癌管理中的作用:文献综述与汇总分析
Ann Hepatobiliary Pancreat Surg. 2020 Feb;24(1):6-16. doi: 10.14701/ahbps.2020.24.1.6. Epub 2020 Feb 27.
9
Cancer statistics, 2020.癌症统计数据,2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
10
Increased multimodality treatment options has improved survival for Hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged.增加多模态治疗选择提高了肝细胞癌的生存率,但胆道癌的生存率仍未改变。
Eur J Surg Oncol. 2019 Sep;45(9):1660-1667. doi: 10.1016/j.ejso.2019.04.002. Epub 2019 Apr 9.